NUCALA POWDER FOR SOLUTION

Country: Canada

Language: English

Source: Health Canada

Active ingredient:

MEPOLIZUMAB

Available from:

GLAXOSMITHKLINE INC

ATC code:

R03DX09

INN (International Name):

MEPOLIZUMAB

Dosage:

100MG

Pharmaceutical form:

POWDER FOR SOLUTION

Composition:

MEPOLIZUMAB 100MG

Administration route:

SUBCUTANEOUS

Units in package:

1.2ML

Prescription type:

Prescription

Therapeutic area:

IMMUNOSUPPRESSIVE AGENTS

Product summary:

Active ingredient group (AIG) number: 0157630001; AHFS:

Authorization status:

CANCELLED POST MARKET

Authorization date:

2023-12-06

Summary of Product characteristics

_ _
_ _
_ _
_ May 26, 2022_
_ _
_NUCALA, Mepolizumab _
_ Page 1 of 85_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
NUCALA
Mepolizumab for Injection
100 mg/mL lyophilized powder for subcutaneous injection
Mepolizumab Injection
100 mg/mL solution for subcutaneous injection
40 mg/0.4 mL solution for subcutaneous injection
Interleukin-5 (IL-5) inhibitor
GlaxoSmithKline Inc.
100 Milverton Drive
Suite 800
Mississauga, Ontario
L5R 4H1
Date of Initial Authorization:
April 6, 2016
Date of Revision:
September 15, 2022
SUBMISSION CONTROL NO: 257207
_©_
_2022 GSK group of companies of its licensor _
_Trademarks are owned by or licensed to the GSK group of companies _
_ _
_ _
_ _
_ May 26, 2022_
_ _
_NUCALA, Mepolizumab _
_ Page 2 of 85_
RECENT MAJOR LABEL CHANGES
SECTION
DATE
1 INDICATIONS
11/2021
4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations
05/2022
4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose &
Dosage Adjustment
05/2022
4 DOSAGE AND ADMINISTRATION, 4.4 Administration
05/2022
4 DOSAGE AND ADMINISTRATION, 4.5 Missed Dose
05/2022
7 WARNINGS AND PRECAUTIONS, 7.1 Special Populations
11/2021
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1 Pediatrics
.....................................................................................................................
4
1.2 Geriatrics
.....................................................................................................................
5
2
CONTRAINDICATIONS
...............................